Coerente Capital Management Purchases 34,339 Shares of Pfizer Inc. $PFE

Coerente Capital Management boosted its holdings in Pfizer Inc. (NYSE:PFE) by 5.1% in the first quarter, HoldingsChannel reports. The institutional investor owned 701,344 shares of the biopharmaceutical company’s stock after purchasing an additional 34,339 shares during the quarter. Pfizer makes up 3.7% of Coerente Capital Management’s portfolio, making the stock its 15th largest position. Coerente Capital Management’s holdings in Pfizer were worth $19,694,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Vermillion Wealth Management Inc. boosted its stake in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the period. Triad Wealth Partners LLC raised its stake in Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the period. ETF Store Inc. lifted its holdings in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC lifted its holdings in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 400 shares in the last quarter. Finally, Pines Wealth Management LLC boosted its stake in Pfizer by 4.4% in the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 400 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, Guggenheim raised their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.82.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is getting credit for longer-term growth optionality in obesity and broader healthcare innovation, with some commentary highlighting its pipeline as an underappreciated driver and its use of AI to improve operations. Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Positive Sentiment: Several articles point to Pfizer’s dividend yield and its obesity pipeline as reasons some investors remain interested in the stock while waiting for new products to ramp. Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
• Neutral Sentiment: Pfizer said it will host a webcast of its August 4 second-quarter 2026 results call, which is a routine investor update rather than a direct catalyst. Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• Neutral Sentiment: Nike named Pfizer finance executive David Denton as its next CFO, which reflects positively on Pfizer’s leadership bench but is not a direct operating update for PFE shares. Nike Names Pfizer’s Denton as Next CFO
• Negative Sentiment: Pfizer’s experimental lung cancer drug sigvotatug vedotin failed to meet the main overall-survival goal in a late-stage trial versus chemotherapy, a setback that is weighing on sentiment around the stock today. Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: While the drug showed benefit in some subgroups, the mixed readout underscores ongoing execution risk in Pfizer’s oncology portfolio, especially for assets tied to its Seagen acquisition. Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial

Pfizer Stock Down 1.3%

Shares of NYSE PFE opened at $24.75 on Wednesday. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm’s 50-day moving average price is $26.13 and its 200-day moving average price is $26.33. The stock has a market capitalization of $141.06 billion, a price-to-earnings ratio of 18.89 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.